Catalyst Pharmaceuticals Inc  

(Public, NASDAQ:CPRX)   Watch this stock  
Find more results for CPRX
0.00 (0.00%)
Apr 25 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.63 - 1.70
52 week 0.51 - 2.17
Open 1.65
Vol / Avg. 0.00/2.02M
Mkt cap 136.91M
P/E     -
Div/yield     -
EPS -0.22
Shares 82.97M
Beta 2.16
Inst. own 29%
May 8, 2017
Q1 2017 Catalyst Pharmaceuticals Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Mar 16, 2017
Q4 2016 Catalyst Pharmaceuticals Inc Earnings Call
Mar 15, 2017
Q4 2016 Catalyst Pharmaceuticals Inc Earnings Release
Mar 13, 2017
Catalyst Pharmaceuticals Inc at ROTH Conference
Feb 14, 2017
Catalyst Pharmaceuticals Inc at SunTrust Robinson Humphrey Orphan Drug Day
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '16) 2016
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -38.38% -35.50%
Return on average equity -40.62% -38.13%
Employees 18 -
CDP Score - -


355 Alhambra Cir Ste 1250
CORAL GABLES, FL 33134-5038
United States - Map
+1-305-5292522 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Catalyst Pharmaceuticals, Inc., formerly Catalyst Pharmaceutical Partners, Inc., is a development-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for people with rare debilitating diseases. The Company has three drugs in development: Firdapse, CPP-109 and CPP-115. The Company's Firdapse is indicated for the treatments of lambert-eaton myasthenic syndrome (LEMS) and congenital myasthenic syndromes (CMS). Firdapse consists of the phosphate salt of amifampridine. The Company has completed the Phase III trial of Firdapse. The Company's CPP-109 (vigabatrin) is a gamma-aminobutyric acid (GABA) aminotransferase inhibitor. CPP-109 is indicated for the treatment of Tourette's Disorder. The Company's CPP-115 is a GABA aminotransferase inhibitor. CPP-115 is indicated for the treatment of selected neurological indications, such as complex partial seizures and Tourette's Disorder, and epilepsy.

Officers and directors

Patrick James McEnany Chairman of the Board, President, Chief Executive Officer
Age: 68
Bio & Compensation  - Reuters
Alicia Grande CPA Chief Financial Officer, Vice President, Treasurer
Age: 44
Bio & Compensation  - Reuters
Steven R. Miller Ph.D. Chief Operating Officer, Chief Scientific Officer
Age: 53
Bio & Compensation  - Reuters
David D. Muth Executive Vice President, Chief Commercial Officer
Age: 60
Bio & Compensation  - Reuters
M. Douglas Winship Vice President - Regulatory Operations
Age: 66
Bio & Compensation  - Reuters
David J. Caponera Vice President - Patient Advocacy & Reimbursement
Age: 58
Bio & Compensation  - Reuters
Bernardino Mosquera M.D. Vice President - Clinical Operations
Age: 47
Bio & Compensation  - Reuters
Charles B. O'Keeffe Lead Independent Director
Age: 75
Bio & Compensation  - Reuters
Gary Ingenito M.D. Chief Medical Officer
Age: 52
Bio & Compensation  - Reuters
Richard J. Daly Director
Age: 55
Bio & Compensation  - Reuters